Recent Updates
Recently added Catalysts
CRIS Neutral Sentiment

Hadassah University MC

Wednesday, October 23, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: Hadassah University Medical Center provides an overview of its management, collaborations, and patient studies. The article outlines its pipeline, including drugs like Emavusertib and Fimepinostat, and details on current studies related to lymphoma and leukemia. It also highlights the institution's commitment to patient care and research.
Price reaction · baseline $109 (2024-10-22 close) · hit pre-market · 36 other CRIS headline(s) in the window, move may be shared
day 0 close · peak
-4.2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What is Hadassah University Medical Center known for?

Hadassah University Medical Center is recognized for its management, collaborations, and research in patient care.

What studies are currently sponsored by Hadassah?

Current studies include TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL.

What drugs are included in Hadassah's pipeline?

The pipeline includes Emavusertib (CA-4948), Fimepinostat, CA-170, and CA-327.

How does Hadassah support patients?

Hadassah offers a compassionate use policy and conducts various studies to support patients.

ShareAdd on Google
Tags: CRIS Viatris Investor Conferences Healthcare Hadassah University Emavusertib TakeAim Lymphoma TakeAim Leukemia
Last updated: Oct 23, 2024

Biotech snapshot

Cash runway
$5M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
EmavusertibPhase 2
Chronic Lymphocytic Leukemia →